Can we speak today of a phosphorus value as an indicator of dialysis treatment quality?
Abstract
Introduction: Bone and mineral metabolism disorder is a serious complication of Chronic Kidney Disease. Concerning phosphorus, the new KDIGO Guidelines suggest a reduction of hyperphosphatemia, but they do not recommend a specific value. However, in Argentina, a phosphorus value of 5 mg/dL or less is used as a dialysis quality indicator (DiaQualInd). Our objective was to evaluate whether this goal is currently valid as a DiaQualInd. Methods: A multicentric, crosssectional study was conducted. Patients older than 18 were included, with more than 90 days undergoing hemodialysis. Demographic and laboratory data were tabulated, comparing normophosphatemic with hyperphosphatemic values. According to this method, in 3 centers the upper reference limit was 4.5 mg/dL and in 4 centers it was 5.6 mg/dL. The latter were analyzed as a separate group (F 5.6). Results: There were 333 patients included in this study. Age, sex, AVF percentage, diabetes, time on dialysis, Kt/V, hemoglobin and albumin were similar to the registry data. The median phosphatemia was 5.2 mg/dL, (range: 2.3 to 10.6). The hyperphosphatemic patients were the youngest, spent less time on dialysis and showed higher hemoglobin and albumin values. In group F 5.6 (n = 203), according to KDIGO only 33.7% would need treatment. If this DiaQualInd were to be applied (phosphorus lower than 5 mg/dL), the percentage would be 55%, that is, 21.3% of normophosphatemic patients should be treated. Conclusions: Phosphatemia determination should be standardized before using a fixed value such as DiaQualInd.References
Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol. 2013;8(12):2132-40.
Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-30.
Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(12):2251-7.
Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63(6):979-87.
Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167(9):879-85.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.
Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737-51.
Grupo de Metabolismo Óseo y Mineral, Sociedad Argentina de Nefrología. 2º Consenso de metabolismo óseo-mineral [Internet]. Resumen de bolsillo. Buenos Aires: SAN, 2017. 64 p. Disponible en: http://san.org.ar/2015/docs/consensos/B94_Consenso_SAN2.pdf (Consulta: 04/01/2018).
Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest. 1987;80(4):1147-54.
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18.
Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30(9):1542-51.
Fouque D, Roth H, Darné B, Jean-Bouchet L, Daugas E, Drüeke TB, et al. Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study. Clin Kidney J. 2018;11(1):73-9.
Siga E, Fernández M, Galarza M, Mesina V, De Palma H, Coste R. Difference between true functional haemoglobin and pre-dialysis haemoglobin is associated with plasma volume variation: a multicentre study. Int Urol Nephrol. 2014;46(12):2379-84.
Epidat: programa para análisis epidemiológico de datos (versión 4.2, jul. 2016) [Internet]. Consellería de Sanidade, Xunta de Galicia(España); Organización Panamericana de la Salud (Ginebra); Universidad CES (Colombia). Disponible en: https://www.picuida.es/programa-estadistico-epidat-4-2-version-julio-2016/ (Consulta: 04/01/2018).
Marinovich S, Lavorato C, Celia E, Bisignano L, Soratti M, Hansen Krogh D, Tagliafichi V, Moriñigo C, Rosa Diez G, Fernández V. Registro Argentino de Diálisis Crónica SAN INCUCAI 2008 [Internet]. Sociedad Argentina de Nefrología e Instituto Nacional Central Único Coordinador de Ablación e Implante. Buenos Aires; 2010. Disponible en: http://san.org.ar/2015/docs/registros/REGISTRO_ARGENTINO_dialConica2014_2015.pdf (Consulta: 04/01/2018)
Tessey A, Celia E, Ducasse E. Calidad en diálisis. Indicadores mínimos aplicables a pacientes: prevalentes en tratamiento de diálisis [Internet]. Buenos Aires: Grupo de Trabajo Calidad en Diálisis, Sociedad Argentina de Nefrología; 2014. 27 p. Disponible en: http://san.org.ar/2015/docs/consensos/pub_SAN_ACQ.pdf (Consulta: 04/01/2018)
Port FK, Morgenstern H, Bieber BA, Karaboyas A, McCullough KP, Tentori F, Pisoni RL, et al. Understanding associations of hemodialysis practices with clinical and patient-reported outcomes: examples from the DOPPS. Nephrol Dial Transplant. 2017;32(suppl_2):ii106-ii112.
Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407-15.
Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511-8.
Fouque D, Roth H, Pelletier S, London GM, Hannedouche T, Jean G, et al. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets? Nephrol Dial Transplant. 2013;28(2):360-7.
Douthat WG, Castellano M, Berenguer L, Guzmán MA, De Arteaga J, Chiurchiu CR, et al. Elevada prevalencia de hiperparatiroidismo secundario en pacientes con enfermedad renal crónica en diálisis en Argentina. Nefrología (Madr.) 2013;33(5):657-66.
Marinovich SM, Negri AL. Trastorno mineral y óseo relacionado a la enfermedad renal crónica en pacientes prevalentes en diálisis crónica en el trienio 2011-2013 en Argentina. Rev Nefrol Diál Traspl. 2015;35(1):24-31.
